1. Home
  2. Age-Related Macular Degeneration (ARMD) Doctors Near Me
  3. Clinical Trials
  4. Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This study is being conducted to assess two imaging methods-central microperimetry and radial OCT (Optical Coherence Tomography)-in patients with Geographic Atrophy (GA) or those who are at risk of developing this condition. The study team is trying to determine whether these methods can provide more accurate measurements of GA progression toward the foveal center, the central part of the retina responsible for your sharpest, most detailed vision.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Healthy Volunteers: f
View:

• Subjects must be 55+ years of age Subjects in the Intermediate AMD Observation Arm must have intermediate age-related macular degeneration in one eye

⁃ Subjects in the GA Observation Arm, GA Continuing Treatment Arm, and GA Treatment Arm must have non-central GA (defined as GA has not involved the center point of the fovea) and at least 1% GA in the central 1 mm zone.

Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Jay M Stewart, MD
eyestudy@ucsf.edu
(628) 206-3123
Time Frame
Start Date: 2025-06-11
Estimated Completion Date: 2027-06-11
Participants
Target number of participants: 80
Treatments
Non-central geographic atrophy not being treated
Patients with age-related macular degeneration who have geographic atrophy that does not involve the fovea.
Intermediate age-related macular degeneration
Patients with intermediate age-related macular degeneration
Non-central geographic atrophy currently being treated
Patients with non-central geographic atrophy from age-related macular degeneration who are currently receiving treatment for this condition.
Non-central geographic atrophy initiating treatment
Patients with non-central geographic atrophy from age-related macular degeneration who will be starting to receive treatment for this condition.
Related Therapeutic Areas
Geographic Atrophy
Late-Onset Retinal Degeneration
Age-Related Macular Degeneration (ARMD)
Sponsors
Leads: University of California, San Francisco

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

Enrollment Status: Recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Phase: Phase 2

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Enrollment Status: Recruiting
Publish Date: June 08, 2026

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Enrollment Status: Recruiting
Publish Date: June 17, 2026
Intervention Type: Drug
Study Phase: Phase 3
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved